Industry Perspectives

A breakthrough from AI|ffinity and NexMR was achieved with a 100-fold affinity improvement in the initial round of drug discovery using ultrafast NMR screening and AI-driven lead generation against intrinsically disordered protein targets.

Optimizing CRISPR delivery is essential to unlocking its full potential in drug discovery, enabling efficient, precise, and reproducible gene editing across diverse cell types and experimental contexts.

Peer-reviewed study in the International Wound Journal indicates that Aurase Wound Gel can achieve debridement without any additional pain to the patient

Bio-Rad Laboratories, Inc has launched four new Droplet Digital PCR platforms.

Proceeds will accelerate Optibrium’s product development and expand the global reach of its computational chemistry and AI-driven discovery technology

Expanding capabilities in delivering scalable, high-quality synthetic DNA solutions to the global market

Artificial intelligence is prompting a fundamental rethink of clinical trial design and execution, with the potential to reduce patient burden, improve data quality, and accelerate development timelines. 

As demand grows for high-resolution, multiplexed tissue analysis, automation is key to enabling broader access and clinical application.

Investment to leverage OutSee’s proprietary AI-based predictive genomics technology, Nomaly, to expand and progress in-house target development program

Enhanced Genomics’ 3D multi-omics platform harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches

New Pipeline Graph unifies competitive insights with preclinical research on a single AI platform to accelerate drug target identification and increase commercial success

As supply chain instability and international backorders continue to affect the life sciences and diagnostics sectors, Zymo Research is stepping in with scalable, U.S.-based alternatives.